EMA Application withdrawn: Nugalviq (govorestat) — Advanz Pharma Limited

View source ↗

Summary

The EMA has withdrawn the application for Nugalviq (govorestat) by Advanz Pharma Limited for galactosemias.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Galactosemias

Drugs mentioned

• Nugalviq (govorestat)

Snippet

Status: Application withdrawn. Therapeutic area: Galactosemias. MAH: Advanz Pharma Limited. Orphan medicine